ADVERTISEMENT

The University at Buffalo’s HIV Clinical Pharmacology Research Program has received several National Institutes of Health grants totaling $1.86 million for new initiatives in hepatitis C virus drug development, nanomedicine research for tuberculosis and pharmacogenomics of neurocognitive disorders for people with HIV/AIDS.

The federal awards also expand UB’s HIV pharmacology research to include drug development for hepatitis C and tuberculosis, according to university officials.